Quotient Sciences Completes Integration of Drug Substance into Translational Pharmaceutics Platform

Quotient Sciences announces that it has integrated drug substance into its flagship Translational Pharmaceutics platform.

Quotient Sciences announced on Feb. 17, 2022 that it has integrated drug substance into its flagship Translational Pharmaceutics platform. This newly integrated service combines drug substance, drug product, and clinical testing activities all under one unified organization and project manager.

The approach of combining manufacturing and clinical dosing at a single organization allows innovators to adjust formulations and dosing in real time. Translational Pharmaceutics was developed in consultation with the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and FDA and utilizes a rapid “make-test” cycle, where drug products are manufactured, released, and dosed in a clinical study in days rather than months.

“Our Translational Pharmaceutics platform is now in its 15th year and has accelerated development timelines for more than 500 drug programs,” commented Mark Egerton, CEO of Quotient Sciences, in a press release. “We remain the only outsourcing partner able to offer innovators the ability to manufacture, release and dose under one organization. This approach is proven to shave 12 months off timelines and, by adding drug substance synthesis, the timeline from candidate selection to clinic can be further accelerated by 2–4 months.”

Source: Quotient Sciences